Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06248229 · ClinicalTrials.gov registry record · Phase 4
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
A Phase 4 study of Fatigue and Attention Deficit Hyperactivity Disorder, sponsored by Rochester Center for Behavioral Medicine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06248229: Recruiting Phase 4 study of Fatigue and Attention Deficit Hyperactivity Disorder, sponsored by Rochester Center for Behavioral Medicine.
NCT06248229 is a Phase 4 study of Fatigue and Attention Deficit Hyperactivity Disorder that is actively recruiting participants, run by Rochester Center for Behavioral Medicine. The registered enrollment target is 50 participants, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06248229, a Phase 4 study of Fatigue and Attention Deficit Hyperactivity Disorder, is actively recruiting participants, sponsored by Rochester Center for Behavioral Medicine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to study the impact of Dyanavel on co-occuring fatigue in adults with Attention Deficit/Hyperactivity Disorder. The main question it aims to answer is whether Dyanavel XR leads to a statistically significant reduction in fatigue compared to placebo, as measured by the Fatigue Symptom Inventory.
Primary Outcome
Rating scale completed by study coordinator or PI. Score would be 0-10 with 10 being a worse outcome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dyanavel XR
Study Locations (1)
Michigan
- Rochester Center for Behavioral Medicine - Rochester Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
What NCT06248229 shows while recruiting
NCT06248229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Fatigue appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06248229 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06248229 about?
NCT06248229 is a clinical study titled "A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).". The goal of this clinical trial is to study the impact of Dyanavel on co-occuring fatigue in adults with Attention Deficit/Hyperactivity Disorder. The main question it aims to answer is whether Dyanavel XR leads to a statistically significant reduction in fatigue compared to placebo, as measured by ...
What is the current status of trial NCT06248229?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2024-09-01. Estimated completion is 2026-12-01.
What conditions does trial NCT06248229 study?
This clinical trial studies the following conditions: Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder.
What interventions are being tested in trial NCT06248229?
The interventions under investigation include: Placebo (DRUG), Dyanavel XR (DRUG).
Who is sponsoring clinical trial NCT06248229?
This trial is sponsored by Rochester Center for Behavioral Medicine, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06248229 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06248229's enrollment target sits among peer trials
50 63rd of 109 higher than 45 of 109 other Fatigue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatigue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors
RECRUITING · Phase 4
-
Fatigue and Cognitive Demand With Aging
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Behavioral and Neural Correlates of Post-Stroke Fatigue
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
-
Eccentric Exercise and Fatigue in Multiple Sclerosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI